Why GT Biopharma’s B7-H3 TriKE could reshape immunotherapy for solid tumors
GT Biopharma’s GTB-5550 gets FDA clearance for a Phase 1 solid tumor trial. Find out how this NK cell engager could reshape B7-H3 cancer immunotherapy.
GT Biopharma submits IND for GTB-5550 TriKE targeting B7-H3 expressing solid tumors with NK cell activation
Find out how GT Biopharma’s IND filing for its B7-H3-targeted TriKE GTB-5550 could advance NK cell immunotherapy for solid tumors.